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Abstract
Background: The ABO blood type B3 is the most common B subtype in the Chinese population with a frequency of 1/900.
Although IVS3+5G.A (rs55852701) mutation of B gene has been shown to associate with the development of B3 blood
type, genetic and mechanistic evaluation for the unique mixed-field agglutination phenotype has not yet been completely
addressed.
Methodology/Principal Findings: In this study, we analyzed 16 cases of confirmed B3 individuals and found that
IVS3+5G.A attributes to all cases of B3. RT-PCR analyses revealed the presence of at least 7 types of aberrant B3 splicing
transcripts with most of the transcripts causing early termination and producing non-functional protein during translation.
The splicing transcript without exon 3 that was predicted to generate functional B3 glycosyltransferase lacking 19 amino
acids at the N-terminal segment constituted only 0.9% of the splicing transcripts. Expression of the B3 cDNA with exon 3
deletion in the K562 erythroleukemia cells revealed that the B3 glycosyltransferase had only 40% of B1 activity in converting
H antigen to B antigen. Notably, the typical mixed-field agglutination of B3-RBCs can be mimicked by adding anti-B
antibody to the K562-B3 cells.
Conclusions/Significance: This study thereby demonstrates that both aberrant splicing of B transcripts and the reduced B3
glycosyltransferase activity contribute to weak B expression and the mixed-field agglutination of B3, adding to the
complexity for the regulatory mechanisms of ABO gene expression.
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Introduction
ABO is the most important blood group system in transfusion
medicine [1]. A specific glycosyltransferase encoded by the ABO
gene plays an important role in the modification of ABO blood
antigen [2,3]. The ABO locus spans over 18 kilobases (kb) and
consists of 7 exons which range in size from 26 to 688 base pairs.
Most of the coding sequences lie in exons 6 and 7 [4]. Of the
common ABO alleles, at least two A alleles, one B allele and two O
alleles have been reported [5]. For the A alleles, the sequence of A
1
is the same as the cDNA clone FY-66-1, while A
1v has a single
nucleotide (nt) substitution at position 467 (C to T) that leads to the
substitution of proline to leucine. For the B allele, the sequences
differ from A allele in 7 positions at nt 297, 526, 657, 703, 796, 803
and 930. For the alleles O
1 and O
1v, they share a single nt deletion
(G) at position 261 that results in reading frame shift leading to the
appearance of a stop codon at the positions 353–355. However,
there are five different nt positions between O
1 and O
1v alleles at
297, 646, 681, 771 and 829, respectively.
In addition to the common ABO blood types, distinct blood
types with weak expression of A or B antigens on red blood cells
(RBCs) have been identified and are designated as A3,A x,A el,B 3,
Bx,B el, cis-AB and B(A), respectively [6,7]. Most of the A and B
sub-alleles responsible for the formation of subgroups have been
identified [8–12]. Some of these minor alleles have mutation(s) in
the coding sequences of ABO gene and most of the mutations are
single nt substitution leading to an amino acid alteration. Defect in
RNA splicing also accounts for the occurrence of a number of
blood types. In the case of B3 with typical mixed-field agglutina-
tion of RBCs in the presence of anti-B or anti-AB antibody, a
number of genetic alternations have been reported. In Japan,
Yamamoto et al. reported a B3 case with a 1054C.T substitution
nears the 39-end of the B allele [13]. Ogasawara et al. identified a
B3 case that is generated through gene conversion mechanism
around the nt 646 leading to a 646T.A substitution and lack of B
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have been shown to carry a B allele with a G.A mutation at the
+5 nucleotide of intron 3 (rs55852701) [15]. Such mutation
destroys the consensus of the splice donor site and causes splicing
error leading to exon 3 skipping during mRNA splicing. The B
3
transcript without exon 3 predicts a B glycosyltransferase that lacks
19 amino acids at the N-terminal segment. The frequency of B3
among group AB Chinese persons are approximately 1 in 900
[16]. Although B3 is the most common B subtype in the Chinese
population, only two articles have been published to address the
molecular and genetic basis of B3 [15,17]. The mechanism
responsible for the mixed-field agglutination of B3 RBCs still
awaits to elucidate.
In this study, we comprehensively analyze the splicing
transcripts isolated from B3 individuals in the Taiwanese
population. Notably, we found that the splicing transcripts with
only exon 3 deletion are rare. Many of the splicing variants result
in reading frame shift and generate non-functional B glycosyl-
transferase. Through the use of K562 cell study model, we report
the first experimental evidence that the IVS3+5G.A mutation
alone, independent of the promoter and enhancer activity, is
sufficient to produce the typical mixed-field agglutination in the
presence of anti-B antibody. The significances of these findings are
discussed.
Results
IVS3+5G.A is a common B gene mutation in the B3
subtype of Taiwanese population
Previous studies indicate that B3 individuals in the Taiwanese
population carry the IVS3+5G.A mutation of B allele [15]. To
determine whether IVS3+5G.A is common to B3, DNA samples
from 16 B3 individuals were subject to PCR amplification using
the primer pairs ABOF303 and B3R120 (Table 1). DNA
sequencing revealed that IVS3+5G.A of B allele was present in
all of the 16 DNA samples (Fig. 1). Our data therefore confirm
previous report by Yu et al. and recognize IVS3+5G.A of B allele
as a common mutation for all B3 cases in the Taiwanese
population.
Aberrant splicing transcripts generated by B3 genetic
mutation
According to the theory of RNA splicing, IVS3+5G.A
mutation of B allelle is predicted to cause splicing error and
generates a B3 transcript without exon 3. However, when
attempting to isolate full-length B3 transcripts from the peripheral
blood of B3 individuals, at least two major bands with the sizes of
800–900 bp were observed during agarose gel electrophoresis of
the RT-PCR products. In contrast, only one major band at
approximate 1300 bp was obtained when total RNA from the
peripheral blood of B1 individual was used (Fig. 2). These data
implicate that alternative splicing of B3 transcript is likely to occur
in a more sophisticated way other than splicing out of exon 3 only.
To unveil the splicing variants in B3, we cloned the PCR
products from B3 into Zero Blunt II TOPO vector and randomly
sequenced 102 independent clones to identify the splicing types
Figure 1. The DNA sequences at the boundary of exon 3-intron 3 in blood type B and B3. The DNA sequences between exon 3 and intron
3 in blood type B (upper panel) and B3 (lower panel) case. The B3 individuals have been shown to carry a B allele with a G.A mutation at the +5
nucleotide of intron 3.
doi:10.1371/journal.pone.0037272.g001
Table 1. The primer sequences for generating various ABO
alleles cDNA.
Name Sequence
ABOF303 59-caaaatgccacgcacttcgacctatgatcc-39
B3R120 59-cagagttgagcatgtctacac-39
cDNA1-F 59-aaggcggaggccgagaccagacg-39
cDNA1-R 59-cctaggcttcagttactcacaac-39
cDNA2-F 59-gaattcagccatggccgaggtgttgc-39
cDNA2-R 59-tctagaacaacaggacggacaaaggaaacag-39
ABO exon2-4F 59-cttggtcttgtttggcatggctgttaggga-39
ABO exon2-4R 59-tccctaacagccatgccaaacaagaccaag-39
doi:10.1371/journal.pone.0037272.t001
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types of splicing transcripts were obtained from B3 individuals.
Exon 2/3/6 deletion represented the most abundant splicing
variants with a frequency of 68.6%. In addition, exon 2/3/6
deletion along with intron 6 insertion was the second most
abundant splicing variants with a frequency of 11.8%. The
frequency of exon 2/3 deletion, exon 2/3/4/5/6 deletion, exon 6
deletion, and exon 2/3/4/6 deletion was 8.8%, 6.7%, 1.0%, and
1.0%, respectively. All these splicing variants resulted in frame
shift mutation and produced truncated protein without transferase
activity. Notably, only one clone carried the splicing variant with
exon 3 deletion that was predicted to generate a truncated but
functional transferase (Fig. S2). Our data therefore indicate that
aberrant splicing of B allele is common in B3 cases and the
transcript with exon 3 deletion only was rare with the frequency
less than 1%.
B3 affects surface B antigen expression
Various molecular mechanisms including mutations at the
promoter, enhancer and coding sequences have been proposed to
associate with phenotypic changes for a number of blood types
[18–21]. We previously used K562 cells as a cell study model to
express B
1 cDNA and to investigate ABO antigen expression [22].
Hence, we used the same strategy to stably expressed B
3 cDNA
under the control of cytomegalovirus promoter and determine the
effect of B gene exon 3 deletion on surface B antigen expression.
To compare the levels of antigen expression, the stable lines
expressing B
1 or B
3 cDNA were treated with sodium butyrate to
induce erythroid differentiation and surface expression of B
antigen was measured by the binding of FITC-conjugated lectin
from Bandeiraea simplicifolia (BS-I Isolectin B4) followed by flow
cytometry analysis. As shown in Fig. 3, the parental K562 cells and
the cells transfected with control vector did not express B antigen.
In contrast, B antigen expression was increased in the stable cell
line expressing B
1 or B
3 cDNA. The relative percentage of B
antigen expressing cells were determined for comparing the levels
of B antigen expression in the B1 and B3 sublines (Table 3). The
parental K562 cells that did not express B antigen were used as the
negative control whereas the stable cell line expressing B
1 cDNA
was served as a positive control with the percentage of antigen
expressing cells for B1 setting as 100%. Accordingly, the relative
percentage of B antigen expression for the cells of B3 was 40.92%
of B1. To further delineate the expression levels of B antigen in the
B1 and B3 sublines, the MFI that represents the total B antigen
expression was also compared. We found that the MFI for B3 was
lower than B1 (Table 3). These data thereby demonstrate that
exon 3 deletion of B allele causes a decrease in surface B antigen
expression.
Expression of B3 protein is sufficient to produce mixed-
field agglutination phenotype
Mixed-field agglutination is a typical B3 phenotype when
reacted with the anti-B antibody. To determine whether
expression of exon 3 deletion B3 protein alone is sufficient to
cause mixed-field agglutination, K562-B3 and the control K562
and K562-B1 cells were incubated with the anti-B antibody,
respectively (Fig. 4A). No agglutination was observed for the
control K562 cells. In contrast, large agglutination appeared when
K562-B1 was reacted with the anti-B antibody. Notably, moderate
and small size of agglutination that was similar to the characteristic
mixed-field agglutination of B3 was observed when K562-B3 was
reacted with the anti-B antibody. Quantitative analysis for the size
of agglutination further revealed that K562-B3 distributed mainly
between 5–10 cells/aggregate (Fig. 4B). Large aggregates with
more than 30 cells were only observed for K562-B1. These data
thereby indicate that expression of exon 3 deletion B3 protein is
sufficient to produce the mixed-field agglutination phenotype.
Discussion
B3 is a rare blood type that is characterized by mixed-field
agglutination of RBCs when reacts with anti-B antibody. In this
study, we confirm previous report and identify IVS3+5G.A as the
common B3 mutation in the Taiwanese population. This mutation
causes splicing error and generates mostly non-functional B
transcripts. In contrast, the exon 3 deletion transcript that is
predicted to generate truncated but functional B transferase
accounts for less than 1% of the splicing transcripts in B3
individuals. The B3 transferase is demonstrated to elicit half of the
normal B1 activity as revealed by our cell study model analysis.
Notably, expression of the exon 3 deletion transcript alone is
sufficient to generate mixed-field agglutination in the presence of
anti-B antibody. This study thereby provides the first direct
evidence for the underlying mechanism of mixed-field agglutina-
tion in B3 blood type.
Precise pre-mRNA splicing is catalyzed by the spliceosome that
recognizes conserved sequences at the exon-intron boundaries and
branch point sites [19]. The 59 splicing site (59ss) is composed of
Figure 2. RT-PCR of B1 and B3 transcripts. Buffy coat from the
peripheral blood of B1 (n=3) and B3 (n=3) cases were subject to total
RNA isolation. RT-PCR was then performed to obtain B1 and B3 full-
length cDNA using the primer pair ABOF303 and B3R120. The PCR
products were analyzed by agarose gel electorphoresis analysis.
doi:10.1371/journal.pone.0037272.g002
Table 2. The frequency for the alternative splicing types.
cDNA type Times of clone
Exon 2, 3, 6 deletion 70
Exon 2, 3, 6 deletion+Intron 6 insertion 12
Exon 2, 3 deletion 9
Exon 2, 3, 4, 5, 6 deletion 7
Exon 6 deletion 1
Exon 2, 3, 4, 6 deletion 1
Exon 3 deletion 1
Total 102
doi:10.1371/journal.pone.0037272.t002
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and base pairing to the 59-terminus of U1 snRNA occurs in this
complex [20]. B3 was first reported by Yu et al. as an intronic
mutation at the +5 nucleotide of 59 splicing site in intron 3. Similar
to B3, the Ael phenotype was found to possess an IVS6+5G.A
mutation among Taiwanese and result in weak A [11]. Hence,
single nucleotide substitution of the cis-element in pre-mRNA
splicing machinery not only associate with the development of
various diseases and genetic disorders [23–25], but also accounts
for the genetic changes associated with ABO blood subtypes.
By analyzing the RNA from B3 cases, two different transcripts
corresponding to exon 2-exon 7 with skipping of exon 3 (502 bp)
and the same structure without the exon 3 and exon 6 regions
(367 bp) were previously identified [15]. In this study, we
performed RT-PCR and cloned full-length B transcripts from B3
individuals to comprehensively analyze the types of splicing
transcripts and their relative abundance. Two major findings are
noticed during the analysis. At first, the complexity for the splicing
transcripts is remarkable and exceeds our expectation. At least 7
different splicing transcripts were identified. Most of these
transcripts have exon 3 deletion (101/102), exon 6 deletion (92/
102) and exon 3/exon 6 deletion (102/102). Exon 2 deletion that
has not been reported previously also contributes a major portion
of the splicing transcripts (100/102). The large number of cryptic
splicing types occurs in the B3 individuals implicates the
importance of +5 nucleotide in the 59 splicing site of intron 3
that is essential for appropriate splicing and generating functional
ABO protein.
Secondly, the 7 types of splicing transcripts we identify in this
study are present in B3 individuals with different ratio. The exon
2, 3 and 6 deletion (70/102), exon 2, 3, 6 deletion plus intron 6
insertion (12/102), and exon 2 and 3 deletion (9/102) are the three
major splicing variants. Due to frameshift and early termination,
these three major splicing variants are not predicted to produce
Figure 3. Flow cytometric analysis of B antigen expression. The indicated cell lines were treated with sodium butyrate for 48 h to induce
erythroid differentiation. The cells were then incubated with FITC-conjugated BS-I Isolectin B4 from Bandeiraea simplicifolia. Flow cytometric analyses
were then performed to determine the levels of surface B antigen expression. Representative histograms for the indicated sublines were shown. The
FITC-derived fluorescent intensity was displayed on the x-axis on a logarithmic scale and the number of cells on the y-axis.
doi:10.1371/journal.pone.0037272.g003
Table 3. The B antigen expression for B and B3 subtypes.
Expression constructs Phenotype ISBT number Relative % antigen expressing cellsa MFIa
K562 O 0 -
B1 B1 B101 100 343161530
B3 (intron 3+5G.A) B3 B303 40.92611.78* 18316873*
aThe data represent the mean 6 S.D. (n=10) for the indicated transfectants. The mean percentage of B antigen-expressing cells obtained from B101 was used as
references and was defined as 100%.
*Student t-test was used for statistically analysis with p,0.01 when compared with B101.
doi:10.1371/journal.pone.0037272.t003
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exon 3 deletion were barely present in B3 individual (1/102).
Similar to our findings, Huang et al. reported a CYP17A1
mutation IVS1+2T.C is associated with 17a-hydroxylase defi-
ciency [26]. When the full-length CYP17A1 minigene containing
the intronic mutation was expressed in transfected cells, the
majority (.90%) of mRNA transcripts were incorrectly spliced.
The IVS1+2T.C mutation therefore abolishes most 17a-
hydroxylase/17, 20-lyase enzyme activity by aberrant mRNA
splicing to an intronic pseudo-exon, causing a frame shift and early
termination. Hence, the rare representation of exon 3 deletion B
transcript is likely to associate with the decrease in B glycosyl-
transferase activity for B3 individuals.
At the protein level, the B3 transcript with exon 3 deletion is
predicted to encode a protein with 336 amino acids. According to
the crystal structure of B glycosyltransferase, the protein sequences
corresponding to exon 3 are located at the transmembrane and
mainly the stem region (Fig. 5). The stem region serves as a flexible
tether, allowing the catalytic domain to glycosylate carbohydrate
groups of membrane bound H determinants [3,27,28]. Hence, the
lack of exon 3 likely produces B3 protein that is unstable and
causes a decrease in B3 protein expression. It is also likely that, due
to the short stem region, B3 protein is less flexible and can not
efficiently transfer 1,3-D-galactose to the H protein (Fig. 5). All
these effects can result in reduced B antigen expression on the cell
surface of RBC. Indeed, when B3 cDNA was expressed in the
K562 cell study model, B3 has only 50% of B1 activity in
processing surface B antigen expression that provides a molecular
basis for the decrease in B antigen expression for B3 individuals.
One of the hallmarks of B3 is the mixed-field agglutination
reaction when B3 RBCs are incubated with the anti-B antibody.
This phenomenon appears to correlate with the weak B antigen
expression on the surface of B3 RBCs. Several genetic factors
including base insertions, deletions and substitutions mainly in
exon 6 and 7 [8,29], hybrid alleles [30], splice-site mutations
[15,31], variations in enhancer activity [18–20], promoter
methylation [32], promoter mutations [33] and alternative
promoter regions [21] possess the potential to influence A and B
Figure 4. Expression of B3 cDNA is sufficient to induce typical mixed-field agglutination. A. The indicated K562 sublines were treated
with sodium butyrate to induce erythroid differentiation. The cells were then incubated with anti-B antibody and cell agglutination was observed
using a phase contrast microscope. B. The numbers of aggregation with the indicated number of cells/aggregate were counted. Histogram for the
agglutination size distribution was shown. The data represent the mean 6 S.D. of three independent experiments. P,0.001 by Kruskal-Wallis test.
doi:10.1371/journal.pone.0037272.g004
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agglutination can be replicated simply by incubating B3-expressing
K562 cells with anti-B antibody, indicating that the B3 protein
alone is sufficient to cause the unique mixed-field agglutination.
Hence, we propose two inter-relative mechanisms that cause a
decrease in B surface antigen expression and ultimately mixed-
field agglutination phenotype of B3. At first, IVS3+5G.A
mutation of B gene causes cryptic splicing error and produces at
least 7 alternative splicing types. More than 99% of the splicing
transcripts do not produce functional protein and less than 1% of
the splicing transcripts with exon 3 deletion are predicted to
generate functional B3 protein. Furthermore, B3 protein has only
about half of the normal B function. These two interactive
mechanisms together account for the weak B antigen expression
and ultimately cause the typical mixed-field agglutination of B3.
This study thereby shed new insight for the genetic and
mechanistic effects of IVS3+5G.A on the mixed-field agglutina-
tion phenotype associated with B3.
Mixed-field phenomenon is usually an indicator of B3 blood
type when the anti-B or anti-AB antibody was used in the
agglutination test. Although it is known that B3 individuals in
Taiwan carry the B allele with a G.A mutation at the +5
nucleotide of intron 3, there is still lack of evidence to demonstrate
that B3 phenotype is caused by IVS3+5G.A mutation. On the
other hand, it is also likely that B3 blood type is associated with
other genetic changes as reported previously [13–17]. The cell
study model we reported herein offers a way to confirm whether a
particular ABO gene mutation contributes to the indicated blood
phenotype. This approach is also applicable in the analysis of other
blood types and is thereby important in transfusion medicine.
Materials and Methods
Materials
Human leukemic K562 cells with homozygous O alleles and
surface expression of type H antigens were obtained from
American Type Culture Collection (Manassas, VA). The QIAamp
RNA Blood Mini Kit was purchased from Qiagen (Valencia, CA).
The SuperScript III First-Strand Synthesis System, Zero Blunt
TOPO PCR Cloning kit and Lipofectamine 2000 (LF2000) were
purchased from Invitrogen (Carlsbad, CA). The pCI-neo mam-
malian expression vector was purchased from Promega (Madison,
USA). The sodium butyrate and FITC-conjugated lectin from
Bandeiraea simplicifolia (BS-I Isolectin B4) were purchased from
Sigma (Saint Louis, MO).
Collection of blood specimen from B3 individuals
Typing of ABO blood type was performed by the standard
haemagglutination test. The peripheral blood in K3-EDTA tubes
was obtained from healthy volunteers as control groups with
written informed consent according to the ethical requirements
and regulations of the Chang Gung Memorial Hospital Institute
Review Board, who approved this study. As to the 16 B3
individuals, the specimens were not individually identified after de-
linked process and were analyzed anonymously with the approval
of Chang Gung Memorial Hospital Institute Review Board.
Genomic DNA isolation and PCR
Genomic DNAs of B3 individuals were prepared from their
peripheral blood cells using the QIAamp DNA Blood Mini Kit
(Qiagen GmbH, Hilden, Germany). To determine whether the B
allele has a G.A mutation at the +5 nucleotide of intron 3,
polymerase chain reaction (PCR) was used to amplify the 986 bps
DNA fragment of ABO gene encompassing the region from exon 2
through intron 3 [15]. Briefly, PCR was set up in a reaction
volume of 50 ml containing 1X reaction buffer, 10 nmol of dNTP,
6 pmol of forward and reverse primers (ABOF303 and B3R120,
Table 1), 300 ng of genomic DNA, and 1 mlo fPfu TurboH Hotstart
DNA Polymerase (Stratagene). The cycling condition was 4 min at
94uC for 1 cycle, 30 sec at 94uC, 30 sec at 58uC, and 45 sec at
72uC for 30 cycles, and 10 min at 72uC for 1 cycle. Subsequently,
5 ml of PCR products were fractionated on the 2% agarose gel and
visualized by ethidium bromide staining. The remaining PCR
product was used to carry out direct sequencing using the Big Dye
Terminator Cycle Sequencing kit (Applied Biosystems, Foster
City, CA) and an ABI PRISM 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA) according to the manufacturer’s
instruction.
Figure 5. Schematic representation of the B3 transferase structure and its interaction with galactose residues. The schematic
representation of the B glycosyltransferases is based on previous studies [3,27]. The relative location of the ABO transferase for the cytoplasmic tail,
transmembrane domain, stem region, calalytic domain and the galactose residues are shown. The exons 1 to 7 of the ABO gene encoding for the
different parts of the B glycosyltransferases are indicated. The B glycosyltransferases catalyze the final step of B antigen synthesis by transferring 1,3-
D-galactose residues onto H determinants as the specific acceptor glycoconjugates. As to B3, the lack of exon 3 corresponding to the transmembrane
and stem region of B glycosyltransferase likely produces B3 protein that is unstable and causes a decrease in B3 protein expression. It is also likely that,
due to the short stem region, B3 protein is less flexible and can not efficiently transfer 1,3-D-galactose to the H protein.
doi:10.1371/journal.pone.0037272.g005
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Total RNAs were extracted from 1 ml of peripheral blood by
QIAamp RNA Blood Mini Kit. Reverse transcription (RT) into
complimentary DNA (cDNA) was performed using the Super-
Script III First-Strand Synthesis System and the oligo (dT)-15
primers. Briefly, the total RNA (5 mg) was subjected to RT
reaction (20 ml) containing 2 ml of 10X RT buffer, 2 ml of 0.1 M
dithiothreitol, 1 ml of 10 mM dNTP, 1 mlo f5 0 mM poly(dT)
primer, 1 mlo f4 0 U / ml RNaseOUT and 1 ml of 200 U/ml
SuperScript III reverse transcriptase. The RT condition was 50uC
for 50 min and 85uC for 5 min followed by incubation with 1 mlo f
RNase H for 20 min at 37uC. The RT mixtures were then subject
to PCR in a reaction (50 ml) containing 5 ml of RT product, 5 mlo f
10X PCR buffer (20 mM MgCl2), 4 ml of 2.5 mM dNTP, 2 mlo f
10 mM cDNA1-F and cDNA1-R primers (Table 1), and 1 mlo fPfu
TurboH Hotstart DNA Polymerase (Stratagene). The cycling
condition was 3 min at 95uC for 1 cycle, 30 sec at 94uC, 30 sec
at 65uC, and 1 min at 72uC for 35 cycles, and 10 min at 72uC for
1 cycle. The PCR product was cloned into the pCR4Blunt-TOPO
vector by the Zero Blunt TOPO PCR Cloning kit. The sequences
of the PCR insert were determined using the BigDyeH Terminator
v3.1 Cycle Sequencing Kit.
Site-directed mutagenesis
The B
3 cDNA was generated by site-directed mutagenesis.
Briefly, B101 cDNA was used as the template to generate two
PCR products. At first, a 118 bp DNA fragment of exon 1–4
without exon 3 was amplified by the primer pair cDNA2-F and
exon2-4R (Table 1). Then a 975 bp DNA fragment of exon 2–7
skipping exon 3 was obtained by PCR using the primers exon2-4F
and cDNA2-R. The HotStart pfu DNA polymerase was used for
PCR amplification of cDNA fragments at the cycling condition of
4 min at 94uC for 1 cycle, 30 sec at 94uC, 30 sec at 58uC, and
45 sec at 72uC for 30 cycles, and 10 min at 72uC for 1 cycle. After
purification with QIAquick PCR Purification kit (QIAGEN), the
118 bp and 975 bp PCR products were mixed and the second
PCR was performed using the primers cDNA2-F and cDNA2-R
in the same cycling condition to obtain the B
3 cDNA with exon 3
deletion (1134 bp). The 1134 bp PCR product was cloned into the
pCRII-TOPO vector by a Zero Blunt TOPO PCR Cloning kit
and the sequences were confirmed by DNA sequencing. The
inserted plasmid DNA was subsequently digested with Eco RI and
Xba I and inserted into the pCI-neo mammalian expression vector.
All constructs were validated by DNA sequencing analysis.
Stable transfection
The K562 cells (1610
6) were routinely cultured in 90% Roswell
Park Memorial Institute (RPMI) 1640 medium supplemented with
10% fetal bovine serum, penicillin (50 U/mL) and streptomycin
(50 mg/mL), and were transfected with 5 mg of plasmid DNA
using LF2000 according to the manufacturer’s instructions. The
stable clones were selected by antibiotic resistance in the growth
medium containing 400 mg/mL of G418 for 2 weeks. The
transfectants (3610
5) were stimulated by sodium butyrate to
induce erythroid differentiation. Forty-eight h later, the cells were
harvested and subject to flow cytometry to analyze B and B3
antigen expression.
Flow cytometry analysis
For B antigen detection, K562 cells or the transfectants (3610
5)
were washed twice with 1X phosphate-buffered saline (PBS) and
were incubated for 60 min at room temperature with FITC-
conjugated lectin from Bandeiraea simplicifolia (BS-I Isolectin B4).
After two washes with 1X PBS, the cells were analyzed on a flow
cytometer (FACScan). Two variables, the percentage of antigen-
expressing cells and the mean fluorescence intensity (MFI), were
used for data analysis. MFI is a relative measurment for the
amount of antigen expression on the cell surface. The parental
K562 cells were used as a reference control.
Mixed-field agglutination assay
The K562-B3 and K562 control cells (3610
5) were stimulated
by sodium butyrate to induce erythroid differentiation. Forty-eight
h later, the cells were adjusted to 5610
6/ml and reacted with the
anti-B antibody (Immucor Gamma, Norcross, GA) to demonstrate
the typical mixed-field agglutination. The number of agglutination
in a region of 1 mm61m m 60.1 mm was counted manually using
haemocytometer under the microscope magnification of 1006.
Statistical analysis
The data was analyzed using the SPSS 18 software (PASW
statistics 18.0). The relative percentage of B antigen expression for
the cells of B and B3 were compared using the Student t-test. The
numbers of aggregate with the indicated number of cells/
aggregate were not normally distributed; therefore, the compar-
ison between K562, K562-B and K562-B3 was done using
nonparametric Kruskal-Wallis one-way analysis of variance. The
mean differences with p,0.05 were considered statistically
significant.
Supporting Information
Figure S1 A. The sequences for the cDNA clone skipping of
exon 6. Note the direct link for the sequences of exon 5 to exon 7.
B. The sequences for the cDNA clone skipping of exons 2 and 3.
Note the direct link for the sequences of exon 1 to exon 4. C. The
sequences for the cDNA clone skipping of exons 2, 3 and 6. Note
the direct link for the sequences of exon 1 to exon 4, and exon 5 to
exon 7. D. The sequences for the cDNA clone skipping of exons 2,
3, 4 and 6. Note the direct link for the sequences of exon 1 to exon
5 and exon 5 to exon 7. E. The sequences for the cDNA clone
skipping of exons 2 to 6. Note the direct link for the sequences of
exon 1 to exon 7. F. The sequences for the cDNA clone skipping of
exons 2 and 3, and intron 6 insertion. Note the direct link for the
sequences of exon 1 to exon 4 and the intron 6 insertion.
(TIF)
Figure S2 The B3 transcript with exon 3 deletion. The
sequences for the cDNA clone skipping of exon 3 were shown.
(TIF)
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